FLUOCINONIDE ACETONIDE
Clinical safety rating: safe
No significant drug interactions Systemic absorption can occur with extensive use.
Fluocinonide acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
| Metabolism | Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. |
| Excretion | Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% unchanged drug in urine; biliary/fecal excretion accounts for ~60% of metabolites. |
| Half-life | Terminal elimination half-life is approximately 48-72 hours; prolonged in hepatic impairment due to reduced clearance; duration of action at skin sites persists up to 4-6 hours post-application. |
| Protein binding | ~90-95% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Approximately 0.7 L/kg (highly variable due to lipophilicity); reflects extensive tissue distribution, particularly to skin and adipose tissue. |
| Bioavailability | Topical: <1% systemic bioavailability with intact skin (varies by site, occlusion, and lesion severity); up to 5-10% with damaged skin or occlusion; oral not commercially available; parenteral not indicated. |
| Onset of Action | Topical: 1-2 hours for vasoconstriction (blanching); anti-inflammatory effect begins within 2-3 days of regular application. |
| Duration of Action | Topical: Anti-inflammatory effect lasts 6-12 hours after single application; therapeutic effect maintained with twice-daily dosing; systemic duration limited by adrenal suppression risk with prolonged use. |
| Molecular Weight | 452.5 |
Apply a thin film to affected area 1 to 3 times daily, depending on severity. Maximum: 2 weeks continuous use. Not for use on face, groin, or axillae. Dispense 15-60 g per application.
| Dosage form | OIL |
| Renal impairment | No dosage adjustment necessary for topical use. Systemic absorption is minimal; no specific GFR-based modifications required. |
| Liver impairment | No dosage adjustment necessary for topical use. Systemic absorption is minimal; no specific Child-Pugh based modifications required. |
| Pediatric use | Apply a thin film to affected area 1 to 2 times daily. Limit treatment duration to 5 days. Use lowest potency and smallest amount. Not recommended in children under 2 years of age. |
| Geriatric use | Use with caution due to thinner skin and increased risk of skin atrophy and systemic absorption. Apply sparingly, limit treatment area, and avoid prolonged use. No specific dose adjustment. |
| 1st trimester | Topical corticosteroids are generally avoided during first trimester due to theoretical risk of cleft palate; use only if benefit outweighs risk. |
| 2nd trimester | Limited data; use lowest potency for shortest duration possible. Avoid large areas or occlusive dressings. |
| 3rd trimester | May cause fetal growth restriction or adrenal suppression if used extensively; use with caution. |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| FDA category | Animal |
| Placental transfer | Minimal with topical use, but increased with occlusive dressings or inflamed skin; systemic absorption after topical application is low but can cross placenta. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to fluocinonide or any componentViral skin infections (e.g., herpes simplex, varicella)Fungal skin infectionsBacterial skin infections (unless appropriate antimicrobial therapy is also used)RosaceaPerioral dermatitis
| Precautions | Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, Prolonged use may increase risk of local and systemic infections, Avoid use on face, axillae, and groin due to higher risk of skin atrophy, Discontinue if irritation develops, Use caution in pediatric patients due to greater susceptibility to systemic toxicity, Can mask signs of infection |
| Food/Dietary | No known food interactions. No dietary restrictions required. |
Loading safety data…
| Not recommended in breastfeeding; potential for systemic absorption and adverse effects in infant. Avoid application to breast area. |
| Lactation Rating | L3 (Moderately Safe) or Avoid, depending on potency |
| Teratogenic Risk | Topical corticosteroids, including fluocinonide acetonide, are generally considered low risk for teratogenicity when used at recommended doses. Systemic absorption is minimal, but high potency or extensive use may increase risk. First trimester: no clear evidence of major malformations; avoid excessive use. Second and third trimesters: risk of intrauterine growth restriction with prolonged high-dose use; use lowest potency and shortest duration possible. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression or Cushing's syndrome with prolonged high-dose use. Fetal monitoring for growth restriction if high-potency or extensive use during second/third trimester. Assess skin integrity and signs of infection at application site. |
| Fertility Effects | No known adverse effects on fertility from topical corticosteroids. Systemic corticosteroids can disrupt ovulation, but this is unlikely with topical use at recommended doses. No specific fertility studies reported for fluocinonide acetonide. |
| Clinical Pearls | Fluocinonide acetonide is a high-potency topical corticosteroid. Use limited to 2 consecutive weeks; avoid occlusion unless directed. Do not use on face, groin, or axillae due to risk of atrophy. Monitor for HPA axis suppression if applied over large surface areas (>20% BSA) or prolonged use. Vehicle selection matters: ointment enhances potency, cream for less dry areas. Use fingertip unit (FTU) for dosing: 1 FTU covers 2 adult hand areas. |
| Patient Advice | Apply a thin layer only to affected skin, avoid healthy skin. · Do not use on broken skin or open wounds. · Wash hands after application unless treating hands. · Do not cover with bandages or dressings unless instructed by your doctor. · Use for the shortest time necessary; do not use for more than 2 weeks without re-evaluation. · Avoid contact with eyes, mouth, and mucous membranes. · Do not use on face, armpits, or groin unless specifically prescribed. · Report any signs of skin thinning, infection, or worsening rash. |